Skip to main content
Premium Trial:

Request an Annual Quote

Sirna to Manufacture Archemix Drug Candidate

NEW YORK, Oct. 27 (GenomeWeb News) - Sirna Therapeutics has signed on to manufacture for Archemix the antithrombin aptamer ARC183, the companies said today.


ARC183 is Archemix's first drug development candidate and is being tested for use as an anti-coagulant/anti-thrombotic in coronary artery bypass graft surgery. Under their arrangement, Sirna will make and supply Archemix with the agent for use in its development efforts through phase IIa clinical trials.


"This collaboration is consistent with our strategy of forming process development and manufacturing agreements ... to generate revenues and maintain our leadership in the nucleic acid chemistry field," Sirna president and CEO Howard Robin said in a statement.


Specific terms of the deal were not disclosed.

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.